These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24026738)

  • 1. Adjunctive yokukansan treatment improved cognitive functions in a patient with schizophrenia.
    Sakamoto S; Ujike H; Takaki M; Mizuki Y; Okahisa Y; Kodama M; Uchitomi Y
    J Neuropsychiatry Clin Neurosci; 2013; 25(3):E39-40. PubMed ID: 24026738
    [No Abstract]   [Full Text] [Related]  

  • 2. Guanfacine treatment of cognitive impairment in schizophrenia.
    Friedman JI; Adler DN; Temporini HD; Kemether E; Harvey PD; White L; Parrella M; Davis KL
    Neuropsychopharmacology; 2001 Sep; 25(3):402-9. PubMed ID: 11522468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study.
    Fervaha G; Agid O; Foussias G; Remington G
    Schizophr Res; 2014 Jan; 152(1):317-8. PubMed ID: 24333003
    [No Abstract]   [Full Text] [Related]  

  • 4. Is cognitive insight relevant to functional capacity in schizophrenia?
    Benoit A; Bowie CR; Lepage M
    Schizophr Res; 2017 Jun; 184():150-151. PubMed ID: 28069313
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive impairments in schizophrenic patients with hyponatremia.
    Schnur DB; Wirkowski E; Reddy R; Decina P; Mukherjee S
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):836-8. PubMed ID: 8373921
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of cognitive deficits in schizophrenia.
    Bowie CR; Harvey PD
    Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function.
    Kaneda Y; Jayathilak K; Meltzer HY
    Psychiatry Res; 2009 Sep; 169(2):178-9. PubMed ID: 19646764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-perceived cognitive deficits and occupational outcome in persons with schizophrenia.
    Verdoux H; Monello F; Goumilloux R; Cougnard A; Prouteau A
    Psychiatry Res; 2010 Jul; 178(2):437-9. PubMed ID: 20478628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absent inhibition of return and sustained facilitation in patients with schizophrenia in tertiary care.
    Wu C; Dagg P; Ward C; Crawford M
    Schizophr Res; 2011 Sep; 131(1-3):266-7. PubMed ID: 21419604
    [No Abstract]   [Full Text] [Related]  

  • 11. Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia.
    Rubin LH; Wehring HJ; Demyanovich H; Sue Carter C; Pournajafi-Nazarloo H; Feldman SM; Earl AK; August S; Gold JM; Kelly DL
    Schizophr Res; 2018 May; 195():409-411. PubMed ID: 28965776
    [No Abstract]   [Full Text] [Related]  

  • 12. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autonoetic awareness associated with the projection of the self into the future: an investigation in schizophrenia.
    de Oliveira H; Cuervo-Lombard C; Salamé P; Danion JM
    Psychiatry Res; 2009 Aug; 169(1):86-7. PubMed ID: 19616311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia.
    Dean B
    Neuropsychopharmacology; 2004 Aug; 29(8):1583-4; author reply 1585-6. PubMed ID: 15266348
    [No Abstract]   [Full Text] [Related]  

  • 15. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms of schizophrenia and social cognition.
    Shean G; Meyer J
    Psychiatry Res; 2009 Dec; 170(2-3):157-60. PubMed ID: 19906436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating cognitive dysfunction in patients with schizophrenia.
    Galletly CA; Clark CR; MacFarlane AC
    J Psychiatry Neurosci; 2000 Mar; 25(2):117-24. PubMed ID: 10740985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance on the Cognitive Estimation Test in schizophrenia.
    Roth RM; Pixley HS; Kruck CL; Garlinghouse MA; Giancola PR; Flashman LA
    Appl Neuropsychol Adult; 2012; 19(2):141-6. PubMed ID: 23373582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the impairment of insight between deficit syndrome and non-deficit syndrome patients with first-episode schizophrenia.
    López-Díaz Á; Galiano-Rus S; Herruzo-Rivas A
    Schizophr Res; 2018 Mar; 193():484-485. PubMed ID: 28821359
    [No Abstract]   [Full Text] [Related]  

  • 20. Does practice make perfect? Results from a Chinese feasibility study of cognitive remediation in schizophrenia.
    Byrne LK; Peng D; McCabe M; Mellor D; Zhang J; Zhang T; Huang J; Xu Y
    Neuropsychol Rehabil; 2013; 23(4):580-96. PubMed ID: 23697371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.